Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells

被引:67
|
作者
Page, Brent D. G. [1 ]
Valerie, Nicholas C. K. [1 ]
Wright, Roni H. G. [2 ,3 ]
Wallner, Olov [1 ]
Isaksson, Rebecka [1 ]
Carter, Megan [4 ]
Rudd, Sean G. [1 ]
Loseva, Olga [1 ]
Jemth, Ann-Sofie [1 ]
Almlof, Ingrid [1 ]
Font-Mateu, Jofre [2 ,3 ]
Llona-Minguez, Sabin [1 ]
Baranczewski, Pawel [5 ]
Jeppsson, Fredrik [1 ]
Homan, Evert [1 ]
Almqvist, Helena [6 ]
Axelsson, Hanna [6 ]
Regmi, Shruti [6 ]
Gustavsson, Anna-Lena [6 ]
Lundback, Thomas [6 ]
Scobie, Martin [1 ]
Stromberg, Kia [1 ]
Stenmark, Pal [4 ]
Beato, Miguel [2 ,3 ]
Helleday, Thomas [1 ]
机构
[1] Karolinska Inst, Div Translat Med & Chem Biol, Dept Med Biochem & Biophys, Sci Life Lab, SE-17121 Solna, Sweden
[2] Barcelona Inst Sci & Technol, CRG, E-09003 Barcelona, Spain
[3] Univ Pompeu Fabra, E-08003 Barcelona, Spain
[4] Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden
[5] Uppsala Univ, Drug Optimizat & Pharmaceut Profiling Platform, Dept Pharm, SE-75123 Uppsala, Sweden
[6] Karolinska Inst, Chem Biol Consortium Sweden, Div Translat Med & Chem Biol, Sci Life Lab,Dept Med Biochem & Biophys, SE-17121 Solna, Sweden
来源
NATURE COMMUNICATIONS | 2018年 / 9卷
基金
加拿大健康研究院; 瑞典研究理事会;
关键词
NUDIX HYDROLASES; PROTEIN; POLY(ADP-RIBOSE); MECHANISMS; ENGAGEMENT; HYDROLYSIS; VALIDATION; EXPRESSION; STABILITY; INSIGHTS;
D O I
10.1038/s41467-017-02293-7
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
With a diverse network of substrates, NUDIX hydrolases have emerged as a key family of nucleotide-metabolizing enzymes. NUDT5 (also called NUDIX5) has been implicated in ADPribose and 8-oxo-guanine metabolism and was recently identified as a rheostat of hormone-dependent gene regulation and proliferation in breast cancer cells. Here, we further elucidate the physiological relevance of known NUDT5 substrates and underscore the biological requirement for NUDT5 in gene regulation and proliferation of breast cancer cells. We confirm the involvement of NUDT5 in ADP-ribose metabolism and dissociate a relationship to oxidized nucleotide sanitation. Furthermore, we identify potent NUDT5 inhibitors, which are optimized to promote maximal NUDT5 cellular target engagement by CETSA. Lead compound, TH5427, blocks progestin-dependent, PAR-derived nuclear ATP synthesis and subsequent chromatin remodeling, gene regulation and proliferation in breast cancer cells. We herein present TH5427 as a promising, targeted inhibitor that can be used to further study NUDT5 activity and ADP-ribose metabolism.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells
    Brent D. G. Page
    Nicholas C. K. Valerie
    Roni H. G. Wright
    Olov Wallner
    Rebecka Isaksson
    Megan Carter
    Sean G. Rudd
    Olga Loseva
    Ann-Sofie Jemth
    Ingrid Almlöf
    Jofre Font-Mateu
    Sabin Llona-Minguez
    Pawel Baranczewski
    Fredrik Jeppsson
    Evert Homan
    Helena Almqvist
    Hanna Axelsson
    Shruti Regmi
    Anna-Lena Gustavsson
    Thomas Lundbäck
    Martin Scobie
    Kia Strömberg
    Pål Stenmark
    Miguel Beato
    Thomas Helleday
    Nature Communications, 9
  • [2] Author Correction: Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells
    Brent D. G. Page
    Nicholas C. K. Valerie
    Roni H. G. Wright
    Olov Wallner
    Rebecka Isaksson
    Megan Carter
    Sean G. Rudd
    Olga Loseva
    Ann-Sofie Jemth
    Ingrid Almlöf
    Jofre Font-Mateu
    Sabin Llona-Minguez
    Pawel Baranczewski
    Fredrik Jeppsson
    Evert Homan
    Helena Almqvist
    Hanna Axelsson
    Shruti Regmi
    Anna-Lena Gustavsson
    Thomas Lundbäck
    Martin Scobie
    Kia Strömberg
    Pål Stenmark
    Miguel Beato
    Thomas Helleday
    Nature Communications, 10
  • [3] Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells (vol 9, 250, 2018)
    Page, Brent D. G.
    Valerie, Nicholas C. K.
    Wright, Roni H. G.
    Wallner, Olov
    Isaksson, Rebecka
    Carter, Megan
    Rudd, Sean G.
    Loseva, Olga
    Jemth, Ann-Sofie
    Almlof, Ingrid
    Font-Mateu, Jofre
    Llona-Minguez, Sabin
    Baranczewski, Pawel
    Jeppsson, Fredrik
    Homan, Evert
    Almqvist, Helena
    Axelsson, Hanna
    Regmi, Shruti
    Gustavsson, Anna-Lena
    Lundback, Thomas
    Scobie, Martin
    Stromberg, Kia
    Stenmark, Pal
    Beato, Miguel
    Helleday, Thomas
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [4] Targeted DNA repair in cancer and new NUDT5 inhibitors to block hormone signalling to target breast cancer
    Helleday, T.
    CANCER RESEARCH, 2020, 80 (04)
  • [5] Identification of promising inhibitors against breast cancer disease by targeting NUDIX hydrolase 5 (NUDT5) biomolecule
    Almansour, Nahlah Makki
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2025, 43 (03): : 1171 - 1182
  • [6] Identification of NUDT5 Inhibitors From Approved Drugs
    Tong, Xin-Yu
    Liao, Xuan
    Gao, Min
    Lv, Bo-Min
    Chen, Xiao-Hui
    Chu, Xin-Yi
    Zhang, Qing-Ye
    Zhang, Hong-Yu
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2020, 7
  • [7] The high expression of NUDT5 indicates poor prognosis of breast cancer by modulating AKT / Cyclin D signaling
    Zhang, He
    Zhang, Li-Qun
    Yang, Cheng-Cheng
    Li, Jin
    Tian, Xin-Yuan
    Li, Dan-Ni
    Cui, Ju
    Cai, Jian-Ping
    PLOS ONE, 2021, 16 (02):
  • [8] Molecular docking based virtual screening of the breast cancer target NUDT5
    Sultana, Razia
    Islam, Monjia
    Haque, Md. Azizul
    Evamoni, Fatematuz Zuhura
    Imran, Zahid Mohammad
    Khanom, Jabunnesa
    Munim, Md. Adnan
    BIOINFORMATION, 2019, 15 (11) : 784 - 789
  • [9] The role of a novel phosphatase NUDT5 in triple-negative breast cancer
    Qian, Jing
    Tahaney, William
    Ma, Yanxia
    Mazumdar, Abhijit
    Brown, Powel
    CANCER RESEARCH, 2022, 82 (04)
  • [10] Repurposing fluvoxamine as an inhibitor for NUDT5 in breast cancer cell: an in silico and in vitro study
    Sumathi Ramasamy
    Kanimozhi Jeyaram
    Aathimoolam Narayanan
    Sankarganesh Arunachalam
    Selvarajan Ethiraj
    Muthumanickam Sankar
    Boomi Pandian
    In Silico Pharmacology, 13 (1)